Global Interferon Alpha-2a Biosimilar Market
140 Pages | Healthcare

Global Interferon Alpha-2a Biosimilar Market Research Report 2021 Professional Edition

  • Published Date : 24-12-2021
  • Pages : 140
  • Report Id : 61749
  • Categories : Healthcare

The global Interferon Alpha-2a Biosimilar market was valued at 295.1 Million USD in 2020 and will grow with a CAGR of 11.36% from 2021 to 2028, based on Research Allied newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.The global average price of Interferon Alpha-2a Biosimilar is in the decreasing trend, from 186.78 USD/Unit in 2013 to 64.67 USD/Unit in 2017. With the situation of global economy, prices will be in decreasing trend in the following five years. The classification of Interferon Alpha-2a Biosimilar includes ordinary type and long-lasting type, and the proportion of ordinary type in 2017 is about 64%, and the proportion is in increasing trend from 2013 to 2017. Interferon Alpha-2a Biosimilar is widely used for hepatitis C, hepatitis B and other diseases. The most proportion of Interferon Alpha-2a Biosimilar is used for hepatitis C, and the proportion in 2017 is 46%. Europe is the largest supplier of Interferon Alpha-2a Biosimilar, with a production market share nearly 70% in 2017. South America is the largest consumption place, with a consumption market share nearly 26% in 2017. Following South America, Europe is the second largest consumption place with the consumption market share of 22%. Market competition is not intense. Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, 3sbio, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
By Market Verdors:
Roche
Biosidus
Zydus Cadila
Nanogen
Amega Biotech
Rhein Minapharm Biogenetics
PROBIOMED
3sbio

By Types:
Long-lasting Type
Ordinary Type

By Applications:
Hepatitis C
Hepatitis B

Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2018-2028 & Sales with a thorough analysis of the market s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2018-2028. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.


1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Interferon Alpha-2a Biosimilar Revenue
1.4 Market Analysis by Type
1.4.1 Global Interferon Alpha-2a Biosimilar Market Size Growth Rate by Type: 2021 VS 2028
1.4.2 Long-lasting Type
1.4.3 Ordinary Type
1.5 Market by Application
1.5.1 Global Interferon Alpha-2a Biosimilar Market Share by Application: 2022-2028
1.5.2 Hepatitis C
1.5.3 Hepatitis B
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Interferon Alpha-2a Biosimilar Market
1.8.1 Global Interferon Alpha-2a Biosimilar Market Status and Outlook (2017-2028)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Interferon Alpha-2a Biosimilar Production Capacity Market Share by Manufacturers (2017-2021)
2.2 Global Interferon Alpha-2a Biosimilar Revenue Market Share by Manufacturers (2017-2021)
2.3 Global Interferon Alpha-2a Biosimilar Average Price by Manufacturers (2017-2021)
2.4 Manufacturers Interferon Alpha-2a Biosimilar Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Interferon Alpha-2a Biosimilar Sales Volume Market Share by Region (2017-2021)
3.2 Global Interferon Alpha-2a Biosimilar Sales Revenue Market Share by Region (2017-2021)
3.3 North America Interferon Alpha-2a Biosimilar Sales Volume
3.3.1 North America Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.3.2 North America Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.4 East Asia Interferon Alpha-2a Biosimilar Sales Volume
3.4.1 East Asia Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.4.2 East Asia Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.5 Europe Interferon Alpha-2a Biosimilar Sales Volume (2017-2021)
3.5.1 Europe Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.5.2 Europe Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.6 South Asia Interferon Alpha-2a Biosimilar Sales Volume (2017-2021)
3.6.1 South Asia Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.6.2 South Asia Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.7 Southeast Asia Interferon Alpha-2a Biosimilar Sales Volume (2017-2021)
3.7.1 Southeast Asia Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.7.2 Southeast Asia Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.8 Middle East Interferon Alpha-2a Biosimilar Sales Volume (2017-2021)
3.8.1 Middle East Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.8.2 Middle East Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.9 Africa Interferon Alpha-2a Biosimilar Sales Volume (2017-2021)
3.9.1 Africa Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.9.2 Africa Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.10 Oceania Interferon Alpha-2a Biosimilar Sales Volume (2017-2021)
3.10.1 Oceania Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.10.2 Oceania Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.11 South America Interferon Alpha-2a Biosimilar Sales Volume (2017-2021)
3.11.1 South America Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.11.2 South America Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
3.12 Rest of the World Interferon Alpha-2a Biosimilar Sales Volume (2017-2021)
3.12.1 Rest of the World Interferon Alpha-2a Biosimilar Sales Volume Growth Rate (2017-2021)
3.12.2 Rest of the World Interferon Alpha-2a Biosimilar Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2021)
4 North America
4.1 North America Interferon Alpha-2a Biosimilar Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Interferon Alpha-2a Biosimilar Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Interferon Alpha-2a Biosimilar Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Interferon Alpha-2a Biosimilar Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Interferon Alpha-2a Biosimilar Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Interferon Alpha-2a Biosimilar Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Interferon Alpha-2a Biosimilar Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Interferon Alpha-2a Biosimilar Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Interferon Alpha-2a Biosimilar Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Interferon Alpha-2a Biosimilar Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Interferon Alpha-2a Biosimilar Sales Volume Market Share by Type (2017-2021)
14.2 Global Interferon Alpha-2a Biosimilar Sales Revenue Market Share by Type (2017-2021)
14.3 Global Interferon Alpha-2a Biosimilar Sales Price by Type (2017-2021)
15 Consumption Analysis by Application
15.1 Global Interferon Alpha-2a Biosimilar Consumption Volume by Application (2017-2021)
15.2 Global Interferon Alpha-2a Biosimilar Consumption Value by Application (2017-2021)
16 Company Profiles and Key Figures in Interferon Alpha-2a Biosimilar Business
16.1 Roche
16.1.1 Roche Company Profile
16.1.2 Roche Interferon Alpha-2a Biosimilar Product Specification
16.1.3 Roche Interferon Alpha-2a Biosimilar Production Capacity, Revenue, Price and Gross Margin (2017-2021)
16.2 Biosidus
16.2.1 Biosidus Company Profile
16.2.2 Biosidus Interferon Alpha-2a Biosimilar Product Specification
16.2.3 Biosidus Interferon Alpha-2a Biosimilar Production Capacity, Revenue, Price and Gross Margin (2017-2021)
16.3 Zydus Cadila
16.3.1 Zydus Cadila Company Profile
16.3.2 Zydus Cadila Interferon Alpha-2a Biosimilar Product Specification
16.3.3 Zydus Cadila Interferon Alpha-2a Biosimilar Production Capacity, Revenue, Price and Gross Margin (2017-2021)
16.4 Nanogen
16.4.1 Nanogen Company Profile
16.4.2 Nanogen Interferon Alpha-2a Biosimilar Product Specification
16.4.3 Nanogen Interferon Alpha-2a Biosimilar Production Capacity, Revenue, Price and Gross Margin (2017-2021)
16.5 Amega Biotech
16.5.1 Amega Biotech Company Profile
16.5.2 Amega Biotech Interferon Alpha-2a Biosimilar Product Specification
16.5.3 Amega Biotech Interferon Alpha-2a Biosimilar Production Capacity, Revenue, Price and Gross Margin (2017-2021)
16.6 Rhein Minapharm Biogenetics
16.6.1 Rhein Minapharm Biogenetics Company Profile
16.6.2 Rhein Minapharm Biogenetics Interferon Alpha-2a Biosimilar Product Specification
16.6.3 Rhein Minapharm Biogenetics Interferon Alpha-2a Biosimilar Production Capacity, Revenue, Price and Gross Margin (2017-2021)
16.7 PROBIOMED
16.7.1 PROBIOMED Company Profile
16.7.2 PROBIOMED Interferon Alpha-2a Biosimilar Product Specification
16.7.3 PROBIOMED Interferon Alpha-2a Biosimilar Production Capacity, Revenue, Price and Gross Margin (2017-2021)
16.8 3sbio
16.8.1 3sbio Company Profile
16.8.2 3sbio Interferon Alpha-2a Biosimilar Product Specification
16.8.3 3sbio Interferon Alpha-2a Biosimilar Production Capacity, Revenue, Price and Gross Margin (2017-2021)
17 Interferon Alpha-2a Biosimilar Manufacturing Cost Analysis
17.1 Interferon Alpha-2a Biosimilar Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Interferon Alpha-2a Biosimilar
17.4 Interferon Alpha-2a Biosimilar Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Interferon Alpha-2a Biosimilar Distributors List
18.3 Interferon Alpha-2a Biosimilar Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Interferon Alpha-2a Biosimilar (2022-2028)
20.2 Global Forecasted Revenue of Interferon Alpha-2a Biosimilar (2022-2028)
20.3 Global Forecasted Price of Interferon Alpha-2a Biosimilar (2017-2028)
20.4 Global Forecasted Production of Interferon Alpha-2a Biosimilar by Region (2022-2028)
20.4.1 North America Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.2 East Asia Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.3 Europe Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.4 South Asia Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.5 Southeast Asia Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.6 Middle East Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.7 Africa Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.8 Oceania Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.9 South America Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.4.10 Rest of the World Interferon Alpha-2a Biosimilar Production, Revenue Forecast (2022-2028)
20.5 Forecast by Type and by Application (2022-2028)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2028)
20.5.2 Global Forecasted Consumption of Interferon Alpha-2a Biosimilar by Application (2022-2028)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
21.2 East Asia Market Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
21.3 Europe Market Forecasted Consumption of Interferon Alpha-2a Biosimilar by Countriy
21.4 South Asia Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
21.5 Southeast Asia Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
21.6 Middle East Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
21.7 Africa Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
21.8 Oceania Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
21.9 South America Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
21.10 Rest of the world Forecasted Consumption of Interferon Alpha-2a Biosimilar by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer

Direct Purchase
Your perfect start with Research Allied


Want to customize this report?

This report can be customized according to your requirements. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase.
RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo RA client logo
×

Avail PDF Sample Reports

You may also be lnterested in..

Research Allied Copyright © 2024 .